

Guillain-Barré Risk From Menactra Under Review

BY MIRIAM E. TUCKER
Senior Writer

ATLANTA — Data available thus far suggest that the overall risk for Guillain-Barré syndrome following receipt of the meningococcal conjugate vaccine is not significantly increased, Dr. Robert L. Davis reported at the winter meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

From July 2005 through January 2007, a total of 19 cases of Guillain-Barré syndrome (GBS) occurring within 6 weeks of vaccination with the meningococcal conjugate vaccine (MCV4/Menactra) were reported to the passive Vaccine Adverse Events Reporting System (VAERS). The

'Not finding any GBS after MCV4 vaccination in 11- to 19-year-olds does not offer substantial reassurance regarding MCV4 safety.'

onset interval was 2-33 days following immunization. Seventeen of the 19 were aged 11-19 years old. Information from the eight managed care organizations participating in the Vaccine Safety Datalink (VSD) indicates that approximately 94% of MCV recipients are 11-19 years old, said Dr. Davis, director of the CDC's Immunization Safety Office.

In the VSD Rapid Cycle Project from April 2006 through January 2007, there were no cases of GBS reported among vaccine recipients aged 11-19 years old within 6 weeks of vaccination. A total of 0-1 case was expected. However, "not finding any GBS after MCV4 vaccination in 11- to 19-year-olds does not offer substantial reassurance regarding MCV4 safety," Dr. Davis said.

The overall observed reporting rate for GBS after MCV4 vaccination in VAERS, 1.78 per million person-months, was not higher than expected.

With use of two data sources, the VSD and the Healthcare Utilization Project (HCUP), the expected rates of GBS are 1.13 and 1.11 per million person-months, respectively. If these data accurately represent the true magnitude of increased risk after MCV4 vaccination, then there would be an excess of just 0.89 cases per million doses of MCV4 administered, Dr. Davis said.

However, there was a difference in rate ratio when vaccine recipients were divided by age, 11- to 14-year-olds vs. 15- to 19-year-olds: For the younger set, the observed vs. expected is 1.0/4.2, for a rate ratio of 0.25 when controlled for season. In contrast, among the 15- to 19-year-olds, the observed/expected ratio is 16/6.5, for a rate ratio of 2.48, again controlling for season.

Seasonality plays a role by age, because the older group is more likely to receive MCV4 prior to school entry whereas the 11- to 14-year-olds are receiving it year-round, Dr. Davis pointed out.

The data are subject to major limitations. On one hand, the passive nature of VAERS means that underreporting is likely, which would raise the risk estimates. On the other, there were no surges in GBS cases reported to VAERS after any of the three notices published in the CDC's Morbidity and Mortality Weekly Report, which would be expected if underreporting were marked, he noted.

"Although there appears to be a small

increased risk for GBS after MCV4 vaccination in the 15- to 19-year-old age category, the inherent limitations of VAERS require that these findings be viewed with caution. Substantial uncertainty exists regarding the risk estimate, using the HCUP or the VSD background incidence rate," he said.

However, he added, "the timing of neurologic symptoms within 1-5 weeks of vaccination among reported cases is of concern."

A larger study led by Harvard Pilgrim is expected to yield additional data regarding the risk for GBS following MCV4 in approximately 2 years.

Ongoing evaluation of GBS after MCV4 vaccination is also being performed within VSD, Dr. Davis said.

All cases of Guillain-Barré syndrome in a patient following receipt of Menactra should be reported to VAERS, online at <http://vaers.hhs.gov> or by calling toll-free at 800-822-7967. ■



Discover Levemir®:
a long-acting basal insulin
with a light touch

Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir® FlexPen®. FlexPen® is the world's #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations. Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005]. Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S. © 2006 Novo Nordisk Inc. 131007 September 2006

Levemir®
insulin detemir (rDNA origin) injection
Lighter years ahead